European Medicines Agency is an important partner in generating real world evidence.

Europe’s lead regulatory authority is very active in working with real work data (RWD) in its pursuit of its statutory goals of: Facilitate development and access to medicines Evaluate applications for marketing authorisation Monitor the safety of medicines across the life cycle Provide reliable information to patients and the public EMA is working towards and … Read more

The 2nd EHDEN & OHDSI Study-a-thon on Rheumatoid Arthritis

Between January 13 and 17, approximately 40 people of all disciplines, from clinical to academic to Data Partners (all with data mapped to the OMOP common data model) gathered in Barcelona for the second EHDEN study-a-thon. This time, research questions were situated in the domain of Rheumatoid Arthritis as we set out to evaluate the … Read more

Launch of the EHDEN Service Provider Directory

At the end of 2019, EHDEN launched the EHDEN ‘Directory of Service Providers’. EHDEN’s main objective is to create an EU-wide eco-system for federated analyses of real world data standardised to the OMOP CDM. By listing all EHDEN certified SMEs in this directory, we enable data partners to easily find the SME of their choice … Read more

Results of the first EHDEN open call for data partners

The EHDEN consortium is pleased to announce that a total of 20 data partners have been selected in the first open call for data partners. Having received a total of 29 eligible applications, these 20 applications were selected by the EHDEN Data Source Prioritisation Committee. Combined, the 20 selected data partners represent over 150 million … Read more

Meet the EHDEN partners – José Luis Oliveira

José Luis Oliveira Associate Professor in Computer Science DETI/IEETA, University of Aveiro (PT) Introduce yourself and your institution? I’m associate professor at the Department of Electronics, Telecommunications and Informatics of the University of Aveiro (UAVR), Portugal. I’m also co-founder of BMD Software, an SME-dedicated to the development of medical imaging solutions, biomedical applications, and knowledge extraction in health and life … Read more

IMI/BD4BO Collaboration at BioDataWorld 2019

On 4-5 December, one of the year’s major real-world data events took place again in Basel, Switzerland: BioDataWorld 2019. Among the almost 2,000 attendees coming from 28 countries, the IMI’s (Innovative Medicines Initiative) BD4BO (Big Data For Better Outcomes) project teams (EHDEN, HARMONY, BigData@Heart, PIONEER and ROADMAP) collaborated to raise awareness about their work and … Read more

Meet the EHDEN partners – Michael Arend

Michael Arend VP, R&D IT Pharma Business Partner RWE, Digital Health, and External Innovation Bayer AG Introduce yourself and your company? I’m Michael Arend and I work in Bayer’s Research & Development IT team as business partner for the observational research functions at Bayer Pharmaceutical. My main assignments are on Real World Data & Evidence, … Read more

EHDEN certifies the next 6 SMEs.

On 9-10 December, EHDEN welcomed the second batch of six SMEs to the Erasmus Medical Centre in Rotterdam. During these two days, the SMEs were certified by EHDEN for their knowledge on standardising health data to the OMOP common data model (CDM) and the installation of the technical infrastructure. With this second batch of six … Read more

‘Data Saves Lives’ unveiled at EPF Congress

Brussels, November 2019 – The European Patients’ Forum (EPF), the European Institute for Innovation through Health Data (i~HD) and other key players from the health data communities launched the ‘Data Saves Lives’ Initiative at the EPF’s Congress in Brussels on the 12 November 2019. Data Saves Lives is a multi-stakeholder initiative that aims to raise … Read more

EHDEN knee replacement study results published in Lancet Rheumatology, truly elevating observational data.

Oxford, 7th November 2019: The IMI European Health Data & Evidence Network (EHDEN) project is pleased to announce the publication of the results of its first ‘study-a-thon’ in Lancet Rheumatology the effectiveness and safety associated with unicompartmental versus total knee replacement, a milestone after its first year.1 The choice of which type of knee replacement … Read more